Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirofiban dosing study in acute ischemic stroke undergoing endovascular therapy
ChiCTR2100044191Phase 4Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tirofiban in ischemic stroke (4 arms), sponsored by Hangzhou First People's Hospital. Primary endpoints: NIHSS score and Intracranial bleeding. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
tirofiban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2100044191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044191.